Rhythm Pharmaceuticals Inc(RYTM)stock report

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity. Setmelanotide serves as replacement therapy for the treatment of melanocortin-4, or MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity. The Company also focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstrom syndrome, POMC heterozygous, and POMC epigenetic disorders.

Market Cap:815.3M; Shares Outstanding:43.9M; Short Interest: 4.8%; Q3 2019(9/30/19): Cash 162M. Loss 36.23M

EPS and Sales:

Date EPS % last year % last quarter
2018.12.31 -2.39 15.55% -46.63%
2019.3.31 -0.84 -40.00% 64.85%
2019.6.30 -2.03 -85.71% -141.67%
2019.9.30 -3.31 -92.02% 63.05%



Insider Transactions:

Institution Ownership:

Total institutions: 105,Reduced 1
Shares hold: 42210k shares. no change
shares% hold: 96.09%,no change

Analyst Ratings:

Leave a Reply